Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
MBX Capital is an early-stage venture capital firm founded in 2021 and based in Claymont, Delaware. The firm focuses on investing in visionary founders within the deep health sector, emphasizing the importance of addressing the root causes of chronic diseases. MBX Capital has a cumulative AUM exceeding $100 million, with an annual deployment capacity of approximately $25 million. The firm has built a diverse portfolio of over 30 companies, primarily in the biotech and healthcare sectors.
MBX Capital's investment strategy is centered around companies that are in their first or second institutional rounds, typically before they reach a $50 million valuation. The firm is agnostic to sector, provided that the companies have a clear vision to make a significant impact on health outcomes. Notable milestones include the successful investment in companies like Vivodyne and Arine, which are at the forefront of addressing chronic health issues.
MBX Capital primarily invests in companies during their pre-seed, seed, and Series A stages, with check sizes ranging from $1 million to $4 million. The firm seeks to acquire at least 5% ownership in its portfolio companies. While MBX Capital is open to global investment opportunities, it primarily focuses on the United States market. The firm is sector agnostic but emphasizes investments in companies that address chronic diseases through innovative solutions.
The investment thesis of MBX Capital revolves around supporting visionary founders who are tackling the root causes of chronic diseases, particularly through the lens of environmental toxins and industrial exposures. The firm looks for companies that integrate biology, chemistry, AI/ML, and clinical medicine to create impactful health solutions. This focus on deep health innovations positions MBX Capital as a key player in the healthcare investment landscape.
MBX Capital's portfolio includes over 30 companies, showcasing a commitment to innovative solutions in the healthcare and biotech sectors. Notable portfolio companies include:
This diverse portfolio reflects MBX Capital's commitment to addressing chronic health issues through innovative technologies and solutions.
Gurdane Bhutani: Managing Partner at MBX Capital, Gurdane has a background in healthcare investment and a strong focus on deep health innovations. He articulates the firm's thesis, emphasizing the importance of addressing environmental factors in chronic disease prevention.
Zeshan Muhammedi: Managing Partner and founding member of MBX Capital, Zeshan is known for his active presence in the venture capital community. He engages with media and platforms like VCSheet to promote the firm's mission and investment strategy.
To pitch MBX Capital, founders should send an email to team@mbxcapital.com. It is important to include a concise overview of the startup, its mission, and how it addresses chronic diseases. Founders should also highlight any innovative technologies or solutions being developed.
MBX Capital typically responds within a few weeks, depending on the volume of inquiries. A warm introduction is not required but can be beneficial in establishing credibility.
In December 2025, MBX Capital announced that it crossed the $100 million milestone in cumulative capital commitments. This achievement reflects the firm's active deployment strategy and commitment to investing in deep health innovations.
Recent investments include a $40 million Series A in Vivodyne, which focuses on growing human tissues for pre-clinical data, and a $30 million Series B in Arine, an AI platform optimizing medication regimens. Other notable investments include $10 million in Freedom Biosciences for next-gen neuropsychiatric treatments and $6 million in Macro Trials.
What are MBX Capital's investment criteria?
MBX Capital invests in companies during their pre-seed, seed, and Series A stages, typically before they reach a $50 million valuation. The firm seeks to acquire at least 5% ownership in its portfolio companies.
How can founders pitch to MBX Capital?
Founders can reach out to MBX Capital via email at team@mbxcapital.com. It is recommended to include a clear vision of how their company addresses chronic diseases and the innovative solutions they offer.
What makes MBX Capital different from other investors?
MBX Capital focuses specifically on deep health innovations that tackle the root causes of chronic diseases, particularly through environmental toxins and industrial exposures. This targeted approach sets them apart in the venture capital landscape.
What is the geographic scope of MBX Capital's investments?
While MBX Capital primarily focuses on the United States, it is open to global investment opportunities, seeking companies that align with its deep health investment thesis.
What is the typical check size for investments?
MBX Capital typically invests between $1 million and $4 million in its portfolio companies, with initial checks generally falling between $1 million and $2.5 million.
What kind of support does MBX Capital provide to its portfolio companies?
MBX Capital adds value by leveraging its expertise in deep health, providing strategic guidance, and facilitating connections within the healthcare ecosystem to support portfolio companies in achieving their goals.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.